Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Enecadin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enecadin SCHEMBL29406882 | 1.00 | HRH3 (0.54) | HRH3MEN1KMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL6587974 | 1.00 | HRH3 (0.54) | HRH3MEN1KMT2ALMNAHTT | |
| Enecadin SCHEMBL678822 | 0.99 | HRH3 (0.55) | HRH3MEN1KMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL6593396 | 0.99 | HRH3 (0.52) | HRH3MEN1KMT2ALMNAHTT | |
| SCHEMBL4602839 | 0.99 | HRH3 (0.55) | HRH3MEN1KMT2ALMNAHTT | |
| Enecadin SCHEMBL5420925 | 0.98 | HRH3 (0.54) | HRH3MEN1KMT2ALMNAHTT | |
| Enecadin SCHEMBL5420920 | 0.98 | HRH3 (0.54) | HRH3MEN1KMT2ALMNAHTT | |
| SCHEMBL4603419 | 0.98 | HRH3 (0.53) | HRH3MEN1KMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL6586710 | 0.96 | KCNH2 (0.53) | HRH3KCNH2ACP1 | |
| Hydrochloric Acid SCHEMBL6587345 | 0.92 | KCNH2 (0.47) | KCNH2ACP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057290-A1 | METHOD OF USING FLIBANSERIN FOR NEUROPROTECTION | SALIX PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | claimed |
| US-20140044803-A1 | METHOD OF USING FLIBANSERIN FOR NEUROPROTECTION | SPROUT PHARMACEUTICALS INC (US) | 2014-02-13 | — | — | US | claimed |
| US-20120035185-A1 | Method of Using Flibanserin for Neuroprotection | SPROUT PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | claimed |
| EP-1608632-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7186564-B2 | Polynucleotides encoding novel cysteine proteases of the calpain superfamily, CAN-12v1 and CAN-12v2. | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7091206-B2 | Process for producing pyrimidine derivative and intermediate thereof | NIPPON SHINYAKU CO., LTD (JP) | 2006-08-15 | — | — | US | disclosed |
| US-7041704-B2 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1589959-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | Dynogen Pharmaceuticals Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1572926-A2 | POLYNUCLEOTIDE ENCODING A NOVEL CYSTEINE PROTEASE OF THE CALPAIN SUPERFAMILY, PROTEASE-42 | Bristol-Myers Squibb Company (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050107353-A1 | Methods of treating lower urinary tract disorders using losigamone | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040023985-A1 | Process for producing pyrimidine derivative and intermediate thereof | NIPPON SHINYAKU CO., LTD. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-20040014093-A1 | Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42 | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-22 | — | — | US | disclosed |
| WO-2003078594-A2 | POLYNUCLEOTIDE ENCODING A NOVEL CYSTEINE PROTEASE OF THE CALPAIN SUPERFAMILY, PROTEASE-42 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-25 | — | — | WO | disclosed |
| US-20030114373-A1 | Polynucleotide encoding a novel cysteine protease of the calpain superfamily, CAN-12, and variants thereof | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | disclosed |
| EP-1318146-A1 | PROCESS FOR PRODUCING PYRIMIDINE DERIVATIVE AND INTERMEDIATE THEREOF | Nippon Shinyaku Co., Ltd. (JP) | 2003-06-11 | — | — | EP | disclosed |
| JP-2003146904-A | THERAPEUTIC AGENT FOR GLAUCOMA | NIPPON SHINYAKU CO LTD | 2003-05-21 | — | — | JP | disclosed |
| US-6191149-B1 | DRUG FOR CEREBROVASCULAR DISEASE | NIPPON SHINYAKU, CO., LTD. (JP) | 2001-02-20 | — | — | US | disclosed |
| US-5945426-A | PREVENT NEURONAL DEATH | NIPPON SHINYAKU CO., LTD. (JP) | 1999-08-31 | — | — | US | disclosed |
| EP-0781766-A1 | HETEROCYCLIC DERIVATIVE AND MEDICINE | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1997-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057290-A1 | METHOD OF USING FLIBANSERIN FOR NEUROPROTECTION | FLNB, BDNF, NLN | HRH3 586/4885KCNH2 780/4885MEN1 3568/4885 |
| US-20040014093-A1 | Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42 | CAPNS1, CAPN1, CAPN2 | HRH3 3532/4885KCNH2 4127/4885MEN1 4721/4885 |
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, TRPV1, VIPR2 | HRH3 456/4885KCNH2 178/4885MEN1 3421/4885 |
| US-20050107353-A1 | Methods of treating lower urinary tract disorders using losigamone | LPXN, TRPM5, SLC10A2 | HRH3 2714/4885KCNH2 269/4885MEN1 3365/4885 |
| US-20140044803-A1 | METHOD OF USING FLIBANSERIN FOR NEUROPROTECTION | FLNB, BDNF, NLN | HRH3 586/4885KCNH2 780/4885MEN1 3568/4885 |
| US-20120035185-A1 | Method of Using Flibanserin for Neuroprotection | FLNB, BDNF, NLN | HRH3 586/4885KCNH2 780/4885MEN1 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.